Overview

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer: a Single-arm, Multicentre, Prospective, Phase II Clinical Trial.

Status:
Not yet recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

This trial used a multicentre, single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel. Patients included in this trial were advanced breast cancer with hormone receptor negative and Her2 negative. The primary endpoint is ORR, and the secondary endpoint is DCR, PFS, OS and safety.

Phase:

Phase 2

Details

Lead Sponsor:

Liaoning Tumor Hospital & Institute

Collaborators:

Anshan Tumor Hospital
Chaoyang Central Hospital
Fukuang General Hospital of Liaoning health industry group
Huludao central hospital

Treatments:

Paclitaxel